文献速递胸部肿瘤

纳武利尤单抗或纳武利尤单抗联合伊匹木单抗治疗复发性恶性胸膜间皮瘤患者(IFCT-1501 MAPS2):一项多中心、开放标签、随机、非比较性2期试验

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2019-01-16

在法国21家医院开展的随机非比较2期试验中,125例一线或二线培美曲塞联合铂类治疗后进展的恶性胸膜间皮瘤患者随机接受纳武利尤单抗单药或联合伊匹木单抗。前108例可评估患者中,12周疾病控制率分别为44%和50%,均达到预设的至少40%的终点;两组3-4级毒性发生率分别为14%和26%,联合组有3例治疗相关死亡。作者认为两种方案均显示有前景的活性,需在更大规模临床试验中确认。

要点

  • 纳武利尤单抗单药或联合伊匹木单抗在复发性恶性胸膜间皮瘤中均达到主要终点,12周疾病控制率分别为44%和50%。
  • 联合组3-4级毒性发生率为26%,高于单药组的14%,联合组报告3例治疗相关死亡。
  • 作者结论为两种方案均显示有前景的活性且毒性未超预期,但需在更大规模临床试验中确认。

核心结论

  • 纳武利尤单抗单药或纳武利尤单抗联合伊匹木单抗在复发性恶性胸膜间皮瘤患者中均显示出有前景的活性,且未出现意外毒性。
  • 作者指出这些方案需在更大规模临床试验中确认。

研究设计与样本

  • 多中心、开放标签、随机、非比较性2期试验,在法国21家医院开展。
  • 纳入年龄≥18岁、ECOG体能状态0-1、组织学证实的一线或二线培美曲塞联合铂类治疗后进展、CT可测量病灶、预期寿命>12周的恶性胸膜间皮瘤患者。
  • 患者按1:1随机分配接受静脉纳武利尤单抗3 mg/kg每2周,或静脉纳武利尤单抗3 mg/kg每2周联合静脉伊匹木单抗1 mg/kg每6周,直至进展或不可接受毒性。
  • 随机分层因素为组织学(上皮样 vs 非上皮样)、治疗线数(二线 vs 三线)和既往化疗敏感性(培美曲塞治疗后进展≥3个月 vs <3个月),采用0.8随机因子的最小化法。
  • 主要终点为盲法独立中心评估的12周疾病控制比例,在前108例合格患者中评估,若至少40%患者达到疾病控制则主要终点达成。

主要发现

  • 2016年3月24日至8月25日共招募125例合格患者,纳武利尤单抗组63例,纳武利尤单抗联合伊匹木单抗组62例。
  • 前108例合格患者中,纳武利尤单抗组54例中24例(44%;95% CI 31-58)达到12周疾病控制,联合组54例中27例(50%;95% CI 37-63)达到12周疾病控制。
  • 意向治疗人群中,纳武利尤单抗组63例中25例(40%;95% CI 28-52)达到12周疾病控制,联合组62例中32例(52%;95% CI 39-64)达到12周疾病控制。
  • 纳武利尤单抗组63例中9例(14%)发生3-4级毒性,联合组61例中16例(26%)发生3-4级毒性。
  • 联合组62例中3例(5%)发生导致死亡的毒性(1例暴发性肝炎、1例脑炎、1例急性肾衰竭),纳武利尤单抗组无导致死亡的毒性。

关键数值与推荐

  • 主要终点预设阈值:至少40%患者达到12周疾病控制。
  • 前108例合格患者中,纳武利尤单抗组12周疾病控制24/54(44%;95% CI 31-58),联合组27/54(50%;95% CI 37-63)。
  • 意向治疗人群中,纳武利尤单抗组12周疾病控制25/63(40%;95% CI 28-52),联合组32/62(52%;95% CI 39-64)。

临床怎么用

  • 作者结论为纳武利尤单抗单药或联合伊匹木单抗在复发性恶性胸膜间皮瘤中均显示有前景的活性且未出现意外毒性,并指出需在更大规模临床试验中确认。

局限性

  • 原文未报告局限性;作者在解释中仅指出这些方案需在更大规模临床试验中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control has been less than 30% in all previous studies of second-line drugs. Preliminary results have suggested that anti-programmed cell death 1 (PD-1) monoclonal antibody could be efficacious in these patients. We thus aimed to prospectively assess the anti-PD-1 monoclonal antibody alone or in combination with anti-cytotoxic T-lymphocyte protein 4 (CTLA-4) antibody in patients with malignant pleural mesothelioma. METHODS: This multicentre randomised, non-comparative, open-label, phase 2 trial was done at 21 hospitals in France. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-1, histologically proven malignant pleural mesothelioma progressing after first-line or second-line pemetrexed and platinum-based treatments, measurable disease by CT, and life expectancy greater than 12 weeks. Patients were randomly allocated (1:1) to receive intravenous nivolumab (3 mg/kg bodyweight) every 2 weeks, or intravenous nivolumab (3 mg/kg every 2 weeks) plus intravenous ipilimumab (1 mg/kg every 6 weeks), given until progression or unacceptable toxicity. Central randomisation was stratified by histology (epithelioid vs non-epithelioid), treatment line (second line vs third line), and chemosensitivity to previous treatment (progression ≥3 months vs <3 months after pemetrexed treatment) and used a minimisation method with a 0·8 random factor. The primary outcome was the proportion of patients who achieved 12-week disease control, assessed by masked independent central review; the primary endpoint would be met if disease control was achieved in at least 40% of patients. The primary endpoint was assessed in the first 108 eligible patients. Efficacy analyses were also done in the intention-to-treat population and safety analyses were done in all patients who received at least one dose of their assigned treatment. This trial is registered at ClinicalTrials.gov, number NCT02716272. FINDINGS: Between March 24 and August 25, 2016, 125 eligible patients were recruited and assigned to either nivolumab (n=63) or nivolumab plus ipilimumab (n=62). In the first 108 eligible patients, 12-week disease control was achieved by 24 (44%; 95% CI 31-58) of 54 patients in the nivolumab group and 27 (50%; 37-63) of 54 patients in the nivolumab plus ipilimumab group. In the intention-to-treat population, 12-week disease control was achieved by 25 (40%; 28-52) of 63 patients in the nivolumab group and 32 (52%; 39-64) of 62 patients in the combination group. Nine (14%) of 63 patients in the nivolumab group and 16 (26%) of 61 patients in the combination group had grade 3-4 toxicities. The most frequent grade 3 adverse events were asthenia (one [2%] in the nivolumab group vs three [5%] in the combination group), asymptomatic increase in aspartate aminotransferase or alanine aminotransferase (none vs four [7%] of each), and asymptomatic lipase increase (two [3%] vs one [2%]). No patients had toxicities leading to death in the nivolumab group, whereas three (5%) of 62 in the combination group did (one fulminant hepatitis, one encephalitis, and one acute kidney failure). INTERPRETATION: Anti-PD-1 nivolumab monotherapy or nivolumab plus anti-CTLA-4 ipilimumab combination therapy both showed promising activity in relapsed patients with malignant pleural mesothelioma, without unexpected toxicity. These regimens require confirmation in larger clinical trials. FUNDING: French Cooperative Thoracic Intergroup.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019. PMID: 30660609. doi:10.1016/S1470-2045(18)30765-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。